News | May 04, 2026
Bristol Myers Squibb begins 2026 with growth momentum
The company’s Growth Portfolio delivered $6.2 billion in revenue
The company’s Growth Portfolio delivered $6.2 billion in revenue
Lifts full-year outlook as obesity drug boom accelerates
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
But acquisition charges drag earnings into loss
The transaction marks a clear portfolio reshuffle for Indoco
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Subscribe To Our Newsletter & Stay Updated
